Menu
Washingtoner
  • Home
  • Financial
  • Technology
  • Boeing
  • Aerospace
  • Daryl Guberman
  • Non-profit
  • ANSI-ANAB
  • Health
Washingtoner

FreezeNit Announces Exclusive Licensing of Novel Non-Toxic Lice Treatment Technology
Washingtoner/10287890

Trending...
  • Monexplora Explains the Options Mechanics Behind March's Tech Selloff and VIX Surge
  • City of Spokane And City Council Announce 2026 Washington State Legislative Outcomes
  • Tacoma: Applications Sought for the City's Events and Recognitions Committee
FreezeNit
Naturally-Derived OTC Gel Eliminates Lice Without Neurotoxins, Launching Spring 2025

MARBLEHEAD, Mass. - Washingtoner -- FreezeNit, a leader in innovative lice treatment solutions, is thrilled to announce the exclusive licensing of a novel over-the-counter (OTC) lice treatment gel designed to provide a safe, naturally-derived, and highly effective alternative to traditional synthetic or pesticide-based lice treatments.

Unlike conventional OTC lice treatments that rely on pesticide-based pyrethroids, which have decreasing efficacy due to lice resistance, this new technology works by a purely mechanical method of action to eliminate lice and their eggs. The patented formula is free from harsh chemicals and instead leverages natural abrasives, such as diatomaceous earth and walnut shell powder, orange oil extract, and conditioning agents to physically shred lice and nits, while being gentle on the hair and scalp.

This addition strengthens FreezeNit's growing product portfolio, reinforcing the company's mission to provide clean, effective, science-backed treatments that parents can trust.

"This is an incredibly exciting milestone for FreezeNit," said Joanna Shu, CEO of FreezeNit. "By securing exclusive rights to this novel technology, we're positioned to be on the cutting edge of first aid treatments that are gentle on kids. Traditional lice treatments have failed parents and kids, but with this gel, lice don't stand a chance."

More on Washingtoner
  • Tacoma: Homicide Investigation – 100 block of east 91st Street
  • UK Financial Ltd Tokenized LTNS 1, A $1.1 T Asset-Backed ERC-3643 Security Token with 11 On-Chain Contracts Verifying, Compliant Real-World Value
  • SelfCare is now HealthCare across America
  • State of TBM 2025 Report: 83% of Organizations Boost Performance & Efficiency
  • Spokane: Call for High School Artists: 2026 Riverfront Park Poster Contest

✔ Clinically Proven – was shown to be 96% effective in a clinical trial.
✔ No Resistance Issues – Unlike permethrin-based treatments, which have seen increased lice resistance, this technology works mechanically—not chemically—so lice cannot develop immunity.
✔ Patented & Protected – This novel formula and method of action is patented in the U.S., Canada, and the EU, ensuring exclusivity in the market.
✔ Class I, 510(k) Exempt – The FDA-regulated status allows for a fast-tracked market entry.

FreezeNit is actively engaging with retailers, distributors, and healthcare providers to bring this breakthrough lice treatment to families everywhere.

FreezeNit is an innovative healthcare company dedicated to revolutionizing first-aid with safe, effective, and science-backed solutions. By leveraging cutting-edge technology and natural alternatives to neurotoxins, FreezeNit provides families with fast, reliable, and pesticide-free treatments for head lice infestations.  For more information, visit www.FreezeNit.com.

Media Contact
Cathy Henry
cathy@freezenit.com
214-924-5992


Source: FreezeNit

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • The Inner Power of Emotional Self-Leadership
  • Dr. Nadene Rose Shares the Secret to True Success: Faith, Obedience, and Divine Purpose
  • Spokane: Armed Barricaded Subject Causes N. Market St To Close
  • Enleaf Founder Joins AI Panel at Møde Campus to Help Spokane-Area Businesses Navigate the AI Shift
  • Tacoma: Lincoln Avenue Bridge to Close April 4 for Major Asphalt Repairs
  • Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause
  • Epic Pictures Group Sets North American Release Date for the Thriller NO ORDINARY HEIST
  • Award-Winning REALTOR® Paige Coker Joins Corcoran DeRonja Real Estate
  • Over 98% of crypto owners globally don't declare taxes, new report find
  • TicTac Group acquires French EdTech company Distrisoft
  • Suspect Arrested in February Shooting in South Tacoma
  • Tacoma: City's Events and Recognitions Committee Announces the City of Destiny Award Winners
  • Mark Dobosz Makes Donorassess.org Free To Every Nonprofit On The Planet
  • Genpak Announces Closure of Utah Manufacturing Facility
  • Systemic Certification Breakdown: Federal Oversight Undermined by ANAB Governance Conflicts (2018–2026)
  • Newborn Care Network Introduces Clinical Standard to Bridge the Six-Week Postpartum Gap
  • The AAA Metamorphosis: How Global Gaming Is Redefining Production Standards
  • Monexplora Explains the Options Mechanics Behind March's Tech Selloff and VIX Surge
  • Spokane: Shooting on Wellesley Leaves One Person Deceased and Another Injured
  • Spokane: District 3 Council Members to Host Community Town Hall
_catLbl0 _catLbl1

Popular on Washingtoner

  • Spokane: Indian Canyon Golf Course Opens Thursday, March 12, 2026
  • Independent Financial Agencies Upgrade City of Tacoma’s Bond Ratings Amid Broader Economic Uncertainty
  • Spokane: City Council Adopts "Immigration Enforcement Free Zones" Ordinance
  • Spokane: Funding Available for Tourism and Cultural Investment Grant
  • Pregis Expands Wind Energy Use, Advancing Progress Toward Net Zero by 2040
  • City of Spokane Launches Residential Light Program
  • ANAB's Fraud Taints AS9100, ISO 9001, ISO 13485 Certs (2018-Present) – Stop Paying Registrars
  • New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory
  • Summit Appoints Javier Cabeza as Data, AI, and Analytics Practice Lead
  • Our Purpose ​ —To give "We The People" their voice back—

Similar on Washingtoner

  • NRx Pharmaceuticals Could Be on the Verge of a Breakout Year as AI, FDA Catalysts, and Mental Health Demand Converge
  • CCHR: Psychiatric Drugs Fuel Rising Death Toll: National Adverse Drug Event Awareness Day Confronts America's Medication Crisis
  • SelfCare is now HealthCare across America
  • LiposoMore™ Redefines Bioavailability: Joyful Nutritional Launches High-Performance Liposomal Vitamin C and Iron for the Global Supplement Market
  • The Inner Power of Emotional Self-Leadership
  • Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause
  • Mark Dobosz Makes Donorassess.org Free To Every Nonprofit On The Planet
  • Newborn Care Network Introduces Clinical Standard to Bridge the Six-Week Postpartum Gap
  • Animal Communicator Vicki Draper Helps Pet Parents Reduce Stress and Improve Behavior Naturally
  • Compliance Alert: Maryland, Texas Regulate Use of Artificial Intelligence in Utilization Reviews
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute